Award
NIH Reporter #5R01AI184416-02
Therapeutic drug monitoring for linezolid in the treatment of rifampin-resistant tuberculosis: a pragmatic randomized controlled trial
Recipient
Not Specified
Award Amount
$464,199.00
Ceiling
$464,199.00
Awarded
December 09, 2025
Identifier
5R01AI184416-02
A pragmatic randomized controlled trial funded by NIAID to evaluate therapeutic drug monitoring for linezolid in rifampin-resistant tuberculosis patients, aiming to optimize treatment and reduce toxicity.
Description
The project focuses on evaluating the efficacy of therapeutic drug monitoring (TDM) for linezolid in patients with rifampin-resistant tuberculosis in South Africa. The study aims to prevent toxicity and discontinuation of therapy by adjusting doses based on plasma concentration levels. The trial will enroll 280 participants and compare TDM with standard care. The project is funded by NIAID and is part of a broader effort to optimize TB treatment regimens.